Table 2.
SNP ID | Gene | base change | Group 1a | Group 2b | OR (95% CI) | P value | Clinical outcomes | subgroup | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
WT | HE | HO | WT | HE | HO | |||||||
rs4150558 | GTF2H1 | T > A | 22 | 6 | 1 | 794 | 96 | 2 | 2.74(1.23–6.09) | 0.013 | anemia | none |
rs10857 | POLD3 | A > C | 65 | 46 | 4 | 342 | 370 | 107 | 0.55(0.39–0.76) | 3.01 × 10−4 | neutropenia | none |
rs6592576 | POLD3 | G > A | 65 | 46 | 4 | 346 | 366 | 108 | 0.56(0.41–0.77) | 3.58 × 10−4 | neutropenia | none |
rs12727 | RPA1 | C > G | 23 | 7 | 4 | 688 | 205 | 18 | 1.81(1.02–3.21) | 0.044 | thrombocytopenia | none |
rs3219281 | POLD1 | G > A | 21 | 10 | 3 | 679 | 222 | 15 | 1.87(1.4–3.34) | 0.035 | thrombocytopenia | none |
rs3219341 | POLD1 | G > A | 21 | 10 | 3 | 679 | 220 | 17 | 1.84(1.03–3.26) | 0.039 | thrombocytopenia | none |
rs1726801 | POLD1 | G > A | 21 | 10 | 3 | 676 | 213 | 17 | 1.86(1.05–3.30) | 0.033 | thrombocytopenia | none |
rs3176721 | XPA | C > A | 92 | 39 | 4 | 385 | 86 | 6 | 1.88(1.28–2.76) | 0.001 | clinical benefit | AC |
rs3218804 | GTF2H4 | G > A | 102 | 32 | 1 | 415 | 62 | 0 | 2.29(1.43–3.66) | 0.001 | clinical benefit | AC |
rs4150558 | GTF2H1 | T > A | 0 | 3 | 0 | 183 | 18 | 1 | 23.45(2.64–208.13) | 0.005 | anemia | SCC |
rs2290280 | CCNH | C > A | 1 | 0 | 2 | 160 | 37 | 8 | 28.53(1.69–481.13) | 0.020 | anemia | SCC |
rs8067195 | RPA1 | A > G | 1 | 0 | 2 | 150 | 46 | 9 | 6.93(1.44–33.49) | 0.016 | anemia | SCC |
rs6416887 | RPA1 | A > G | 1 | 0 | 2 | 142 | 52 | 10 | 6.55(1.32–32.44) | 0.021 | anemia | SCC |
rs4150339 | ERCC5 | A > G | 9 | 4 | 1 | 165 | 34 | 0 | 3.93(1.15–13.41) | 0.029 | gastrointestinal toxicity | SCC |
rs3786136 | RPA1 | G > A | 2 | 2 | 1 | 154 | 49 | 1 | 4.71(1.10–20.12) | 0.037 | thrombocytopenia | SCC |
rs4150339 | ERCC5 | A > G | 13 | 2 | 2 | 242 | 44 | 2 | 3.06(1.15–8.19) | 0.026 | gastrointestinal toxicity | TP |
rs4253002 | ERCC6 | G > A | 12 | 5 | 0 | 274 | 13 | 1 | 7.81(2.27–26.88) | 0.001 | gastrointestinal toxicity | TP |
rs1726801 | POLD1 | G > A | 18 | 11 | 4 | 192 | 66 | 2 | 3.03(1.59–5.77) | 0.001 | neutropenia | TP |
rs1673041 | POLD1 | A > C | 7 | 16 | 10 | 134 | 107 | 20 | 3.46(1.97–6.09) | 1.70 × 10−5 | neutropenia | TP |
rs3219341 | POLD1 | G > A | 18 | 11 | 4 | 193 | 66 | 2 | 3.03(1.59–5.75) | 0.001 | neutropenia | TP |
rs1799793 | ERCC2 | G > A | 2 | 5 | 0 | 196 | 26 | 3 | 7.91(2.02–30.96) | 0.003 | anemia | GP |
rs20580 | LIG1 | A > C | 2 | 15 | 4 | 110 | 85 | 19 | 3.21(1.53–6.74) | 0.002 | gastrointestinal toxicity | GP |
rs4253212 | ERCC6 | G > A | 9 | 3 | 2 | 175 | 41 | 1 | 3.31(1.26–8.72) | 0.015 | neutropenia | GP |
rs4150558 | GTF2H1 | T > A | 9 | 3 | 1 | 239 | 33 | 0 | 4.39(1.37–14.08) | 0.013 | anemia | NP |
rs326222 | DDB2 | A > G | 23 | 22 | 9 | 251 | 165 | 15 | 2.07(1.32–3.23) | 0.001 | neutropenia | age ≤ 58 |
rs12150513 | RPA1 | A > C | 31 | 14 | 7 | 263 | 150 | 12 | 2.18(1.32–3.61) | 0.002 | neutropenia | age ≤ 58 |
rs4150339 | ERCC5 | A > G | 34 | 5 | 3 | 366 | 61 | 0 | 2.53(1.23–5.22) | 0.012 | gastrointestinal toxicity | age>58 |
rs2296147 | ERCC5 | A > G | 24 | 12 | 6 | 272 | 146 | 8 | 2.10(1.21–3.64) | 0.008 | gastrointestinal toxicity | age>58 |
rs4150360 | ERCC5 | G > A | 23 | 13 | 6 | 266 | 152 | 9 | 3.07(1.70–5.55) | 2.12 × 10−4 | gastrointestinal toxicity | age>58 |
rs4771436 | ERCC5 | A > C | 31 | 7 | 3 | 190 | 202 | 33 | 0.37(0.19–0.72) | 0.003 | gastrointestinal toxicity | age>58 |
AC, Adenocarcinoma; SCC, Squamous Cell Carcinoma; TP, Paclitaxel combined with cisplatin regimen; GP, Gemcitabine combined with cisplatin regimen; NP, navelbine combined with cisplatin regimen; OR, Odd ratio; CI, Confidence interval; WT, wild type; HE, heterozygote; HO, mutant homozygote.
aGroup 1 means severe toxicity in toxicity analysis, bad response in clinical benefit or response rate analysis.
bGroup 2 means light toxicity in toxicity analysis, good response in clinical benefit or response rate analysis.